|Company name||Iovance Biotherapeutics, Inc.|
NEW YORK, October 9, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of Iovance stockholders. Our investigation concerns whether Iovance has violated the federal securities laws and/or engaged in other unlawful business practices.
On October 5, 2020, Iovance issued a press release “provid[ing] a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma.” Specifically, Iovance advised investors that “the Company and the [U.S. Food and Drug Administration] have not been able to agree on the required potency assays to fully define its TIL therapy, which is required as part of a BLA [Biologics License Application] submission. The Company is continuing to refine the information from its current potency assays and simultaneously developing additional assays. As a result of these developments, the BLA submission is not expected by the end of 2020.”
On this news, Iovance’s stock price fell $3.96 per share, or 12.35%, to close at $28.10 per share on October 6, 2020.
If you purchased or otherwise acquired Iovance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.